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The ability to predict outcome for an individual patient with 
melanoma is important not only for the prognostic interests 
of the particular patient involved, but also for the design and 
accurate interpretation of surgical and adjuvant therapy stud­
ies. Comparison of prognostic studies between centers in the 
United States and Japan may result in understanding biologic 
differences between the disease as it manifests in whites and 
mongoloids. Studies from the Melanoma Clinical Coopera­
tive Group (U.S.A.) and from Tohoku University (Japan) 
show some significant similarities and some differences. 
Overall five-year survival is quite different for clinical stage I 
P rognostic factors are features either of the tumor or of the patient that can be used to predict which patients are likely to live or die from their melanoma. These factors are important not only to predict outcome and for the selection of appropriate therapy for the individual pa­
tient, but also for what they suggest about the developmental biol­
ogy and natural history of melanoma. In addition, an understanding 
of these factors is essential for the correct evaluation of new experi­
mental therapy trials, whether they are surgical, immunotherapeu­
tic, or chemotherapeutic. Tremendous progress has been achieved 
in the past two decades in delineating these factors. Major advances 
occurred when Clark et al [1] recognized that the anatomic level of 
invasion could indicate groups of patients at low risk, intermediate 
risk, and high risk of dying from metastatic melanoma, and Breslow 
recognized that the thickness of the primary tumor in millimeters 
could be used to obtain the same information. It has been well 
confirmed that, of these two prognostic determinants, thickness is 
the better predictor of outcome, and to date it is the single best 
predictor of outcome of all individual prognostic parameters studied 
for patients with clinical stage I disease (localized disease) [3]. 
Where prognostic factors have been examined in white popula­
tions, they have been reasonably comparable (U.S.A., Australia, 
Netherlands). Several groups using multivariate models have added 
second prognostic factors to thickness in order to further refine 
differences between risk groups. While many of these second fac­
tors seem highly correlated, various groups have emphasized one 
factor over another. The second factors that have been of value 
include ulceration of the primary tumor (as emphasized by Balch et 
al [4]), mitotic rate (as emphasized by Schmoeckel and Braun-Falco 
[5]), subsite (as emphasized by Day [6]), and microscopic satellites 
(as emphasized by Harrist and coworkers [7]). Tumor type, per se, 
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patients, 85% and 65%, respectively. However, when five­
year survival for lesions on the hands and feet in the U.S. 
series is compared with the mainly acral melanomas in the 
Japanese series, the results show five-year survivals of 63% 
and 73%, respectively. Comparison of five-year survivals for 
clinical stage I acral lentigenous melanoma of the soles subdi­
vided by thickness would establish whether data from the 
large series collected in the United States can be extrapolated 
to melanoma behavior in Japan.] Invest DermatoI92:227S-
23 OS, 1989 
probably does not have independent prognostic significance. The 
above factors have emerged from studies of large series of white 
melanoma patients collected at several centers. 
Cutaneous melanoma in Japan has a much lower incidence than 
melanoma in white populations and has a different anatomic distri­
bution. In mongoloid individuals, melanomas are preferentially 
seen on palms, soles, nailbeds, mucous membranes, and the lower 
extremities (other than the sole). The torso and head/neck areas, 
where whites are frequently affected, are infrequent sites in mongo­
loid people. Because melanoma is so much less frequent in Japan, 
the large series upon which melanoma prognostic factors have been 
assessed in whites have not been possible inJapan. What then can be 
learned from a comparative study of prognostic factors in the 
United States and Japan? Does melanoma behave in a similar man­
ner in Japan if site, stage, and thickness are comparable? The re­
mainder of this paper will attempt to examine these issues. 
Table I shows the relevant prognostic factors to be compared in 
the two populations and whether data are available in each category. 
Much of the data for the comparison will be drawn from data of the 
Melanoma Clinical Cooperative Group (NYU - Harvard) repre­
senting studies of U.S. whites [8] and data from Tohoku University, 
Sendai, Japan, representing studies from Japan [9]. These studies 
have been published using similar analytic categories. Critical to the 
accurate comparison of prognostic factors is comparability of a 
given stage in one series with the same stage in another. If stages are 
mixed, then prognostic outcome will depend on the proportion of 
cases in each stage. 
The primary and secondary prognostic factors will each be con­
sidered in turn. Accurate population comparisons would need to 
stratify for site, sex, stage, thickness, ulceration, type, and mitotic 
rate. Multivariate analyses need to be utilized. 
Some important differences exist between demographic aspects 
of melanoma patients in the two populations (see Table II). In Japan 
patients tend to be older at diagnosis and males predominate. 
Tumors are located on acral surfaces or mucosae, and melanomas are 
rarely of the superficial spreading type. Japanese patients tend to 
present with thicker primary lesions and often at a later stage of 
disease. 
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Table I. Major Prognostic Factors 
Data Available 
Factor USA Japan 
Level +, + 
Thickness + + 
Location + + 
Ulceration + + 
Stage + + 
Sex + + 
Mitotic rate + 
Age + 
Microscopic satellites + _b 
• +: Available. 
,-: Not available. 
Anatomic Level of Invasion Table III shows the five-year sur­
vival for patients in the United States and Japan with clinical stage I 
disease by anatomic level of invasion. One shortcoming of the To­
hoku data is the relatively small number of patients (33) in this stage 
available for analysis, in contrast to the approximately 600 patients 
in this category in the MCCG series. The same general trend is 
noted with a fall in survival associated with increasing level of 
invasion, but larger patient numbers are needed to define more 
clearly the intervals in the Tohoku series. Nonetheless, this prog­
nostic variable does show that a low-risk group can be defined in the 
Japanese population (level II) with high survival (100%), and a 
high-risk group with a 50% or lower five-year survival (level V). 
Figure 1 shows the survival separation between anatomic levels in 
the Tohoku population depicted by life table analysis which is simi­
lar to the relationship seen in series with whites. 
Thickness Table IV shows the relationship between five-year 
survival and thickness in millimeters of the primary tumor. As noted 
with level of invasion, low- and high-risk groups can be identified 
in both populations. Lesions <0.76 mm have nearly uniformly cu­
rative outcomes in both populations. Thicker lesions have higher 
risk. Insufficient numbers of patients are available in the Tohoku 
series to assess magnitude of differences between the thickness 
groups. Data from a larger Japanese series of patients confirm that 
the relationship of increasing thickness with worsening prognosis is 
operative in Japanese patients, as in the United States [10]. In this 
retrospective study of 187 patients of all stages, those patients with 
level II lesions or with lesions <0.75 mm thick had a 100% five­
year survival rate. Patients with thicker primary tumors (termed 
stage Ib by the authors) had a five-year survival of 75%. A larger 
prospective series of clinical stage I patients with careful thickness 
measurements will be needed in order to make direct quantitative 
compansons. 
Ulceration Table V shows the adverse effect of ulceration seen in 
the white population, as emphasized by Balch et al [4]. No signifi­
cant adverse effect is seen in the Japanese series, but both Japanese 
groups did as poorly as the ulcerated white group, and it is likely that 
the thickness intervals are not comparable and that the nonulcerated 
Japanese group has a poorer prognosis because of anatomic location 
(palmar-plantar) and high mean thickness. Median thickness in the 
MCCG series was 1.3 mm, while for the Japanese series the median 
Table II. Difference in Factors Affecting Prognosis in the 
MCCG and Tohoku Series 
Median age 
% Female 
% Extremities 
% Superficial spreading melanoma 
% <0.76 
% Ulceration 
MCCG 
50 
51 
44 
71 
28 
31 
Tohoku 
61 
33 
85 
3 
19 
56 
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Table III. Five-Year Survival Rates for Stage I Melanoma by 
Level of Invasion 
Level MCCG Japan (Tohoku) 
II 99% 100% 
III 95% 67% 
IV 75% 50% 
V 39% 50% 
thickness was 1.4 mm for 24 patients with acral melanoma and 
3.5 mm for nine cases with nodular melanoma. 
Mitoses Schmoeckel and Braun-Falco emphasized the importance 
of a high mitotic rate in adding adverse prognostic information to 
thickness [5]. In their studies the product of mitoses/mm2 and 
thickness in millimeters gave a prognostic index that correlated 
better to prognosis than thickness alone. In the MCCG studies 
tumors with?6 mitoses/mm2 had worse prognoses after correcting 
for thickness than tumors with <6 mitoses/mm2 [11]. The NYU 
unit of the MCCG has confirmed the validity of the prognostic 
index (PI) and found that the five-year cumulative survival rates are 
PI = 0-0.99, 95.6% survival; PI = 1.00-10.99, 86.9% survival; 
PI = 11.0-18.99, 73.6% survival; and PI? 19, 44.3% survival 
[12]. I am unaware of data on mitotic rates and effect on prognosis in 
Japanese melanoma series; however, some inference may be gained 
from the paper by Fiebleman et al in which a white population of 
acral lentigenous melanoma (most common type in Japanese popu­
lations) is studied [13]. In this series, 30 of 31 patients were level IV 
or V. No variation in survival was seen in this group by either level 
or thickness. However, when the group was divided into patients 
with tumors having:s 5 mitoses per 10 high-power fields vs patients 
with tumors having more than five mitoses per 10 high-power 
fields, the mean survival was five years and 2.75 years, respectively. 
Should a similar relationship be observed for acral lentigenous mela­
noma in Japan, then the same usefulness of a prognostic index 
would be anticipated. 
Subsite Table VI shows the differences in survival by subsite. Too 
few patients are available for analysis in the Tohoku series to evalu­
ate subsite. Studies must be done correcting for thickness with ade­
quate numbers of patients before quantitative comparisons can be 
made. Of note is the observation in the MCCG data set that tumors 
on a lower extremity do not have uniform prognosis by region. 
Lesions on the feet have a worse prognosis than comparably thick 
lesions elsewhere on the lower extremities [14]. The five-year sur­
vival for lower extremity lesions in Japan of 73% is close to that 
noted for lesions of the hands and feet in the MCCG series, 63%. 
Type Most multivariate analyses eliminate type from the prognos­
tic model. Type, per se, does not appear to add significant informa­
tion to thickness and site. The adverse outcome in Japanese patients 
with primarily nodular and acral melanoma appears based on thick-
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Figure 1. Acturial survival curves according to level of invasion in stage I 
melanoma in Japan (from Balch CM, Milton GW (Eds.): Cutaneous Mela­
noma. JB Lippincott, with permission). 
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Table IV. Five-Year Survival Rates for Stage I Melanoma 
Patients by Thickness 
Thickness (mm) MCCG Tohoku 
<0.76 99% 100% 
0.76-1.49 95% 50% 
1.50-2.49 84% 50% 
2.50-3.99 70% 50% 
2:4.0 44% 67% 
Table V. Five-Year Survival Rates for Stage I Melanoma 
Patients with and without Ulceration of the Primary Tumor 
Ulceration 
Present 
Absent 
MCCG 
68% 
93% 
Tohoku 
63% 
67% 
Table VI. Five-Year Survival Rates for Stage I Melanoma 
Patients by Anatomic Site 
Site MCCG Tohoku 
Lower extremity 92% 73% 
Upper extremity 89% 50% 
Head/neck 82% 50% 
Trunk 80% 
Hands/feet 63% 
Table VII. Five-Year Survival Rates for Stage I Melanoma 
Patients by Sex 
Sex 
Male 
Female 
MCCG 
81% 
90% 
Tohoku 
62% 
100% 
Table VIII. Five-Year Survival by Stage (Tohoku) 
Stage I (localized) 
Stage II (nodal) 
Stage III (distant metastasis) 
/J Two-year survival. 
Mean Thickness 
3.0 mm 
4.7 mm 
Five-Year Survival 
65% 36 patients 
14% 19 patients 
14%' 9 patients 
Table IX. Survival of Stage II Patients in the United States 
(MCCG) and Japan (Tohoku) 
One Year Three Years Five Years 
Stage II MCCG/Japan MCCG/Japan MCCG/Japan 
Number of patients 33'/19 
Overall survival 73/64 52/25 30/14 
, Five had histopathologically negative nodes. 
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ness, ulceration, site, and delay in diagnosis. Biologic behavior of 67 
Japanese cases studied by Jimbow et al did not discern any difference 
in prognosis between acral melanomas and those on other parts of 
the body [15]. 
Sex Nearly all melanoma studies show better survival among fe­
males. The same relationship appears valid in Japan (see Table VII). 
In some multivariate analyses sex drops out, with thickness and 
subsite the dominant factors [6], while in other studies sex remains 
as a significant independent prognostic variable. 
Microscopic Satellites Harrist and Day put forth the concept of 
"microscopic satellites" having adverse prognostic significance in 
addition to thickness [7]. These satellites were defined as the pres­
ence of discrete discontinuous nests of tumor cells at least 0.05 mm 
in diameter separated from the main body of tumor by either reticu­
lar dermal collagen or subcutaneous fat. In the MCCG multivariate 
analyses, this variable was a better predictor of death than either 
mitotic rate or ulceration. Five-year survival was 52% when satel­
lites were present, and 91 % in their absence. No information is 
currently available in the Japanese series on this variable. 
Stage Stage is of utmost importance to outcome. At the present 
time comparable staging systems are not in use in Japan and the 
United States. In the Tohoku series the status of the regional or 
distant lymph nodes was the most important prognostic factor (see 
Table VIII). Five-year survival for Stage I was 65%, for Stage II 
14%, and for Stage III 14% by two years. Five-year survival for 
Stage II MCCG patients was 30%. In the larger Japanese series of 
Jimbow and Kukita, five-year survivals using a four-stage system 
were as follows: Stage Ia (Level II or < 0.75 mm), 100%; Stage Ib, 
75%; Stage II, 50%, Stage III-IV, less than 20% at two years [10]. 
The relationship of stage to prognosis seems similar in the Japanese 
series and the white series (see Table IX). 
CONCLUSION 
An excellent opportunity exists for applying techniques previously 
employed in analyzing melanoma patient survival in the United 
States to the analyses of Japanese series. A larger series of Japanese 
melanoma patients should be compiled with detailed clinical and 
histopathologic parameters recorded. These patients could then be 
compared to site-, type-, and thickness-matched patients in the 
United States series. It is likely that factors operative in white mela­
noma patients will be similar to those operative in mongoloid pa­
tients. 
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